The role of corticosteroids in muscular dystrophy: A critical appraisal
- 31 May 2007
- journal article
- review article
- Published by Wiley in Muscle & Nerve
- Vol. 36 (4) , 424-435
- https://doi.org/10.1002/mus.20812
Abstract
Over the years various steroid trials have been conducted in Duchenne muscular dystrophy (DMD). In children who are still able to walk as well as in those who are wheelchair‐bound, corticosteroids have been found to stabilize muscle strength for a period of time. Controlled clinical observations have shown that some boys remain ambulatory for years longer than reported in natural history data. The two main steroids used are prednisone/prednisolone and deflazacort. They are probably equally effective in stabilizing muscle strength but may have different side‐effect profiles; for instance, deflazacort causes less weight gain. The exact mechanism by which steroids slow the dystrophic process is under investigation. DMD children treated long term also seem to develop other complications of the condition less frequently. For instance, they develop respiratory insufficiency later and have fewer cardiac symptoms. The therapeutic value of corticosteroids is limited, but these drugs represent the best treatment option currently available. Muscle Nerve, 2007Keywords
This publication has 46 references indexed in Scilit:
- The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophyJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Age-Dependent Effect of Myostatin Blockade on Disease Severity in a Murine Model of Limb-Girdle Muscular DystrophyThe American Journal of Pathology, 2006
- Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and preventionNeuromuscular Disorders, 2005
- Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF‐AT pathwayThe FASEB Journal, 2004
- Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies: Part III. Ethical considerationsNeuromuscular Disorders, 2002
- Vertebral compression in Duchenne muscular dystrophy following deflazacortNeuromuscular Disorders, 2002
- Dystrophin‐positive fibers in duchenne dystrophy: Origin and correlation to clinical courseMuscle & Nerve, 1995
- Deflazacort in Duchenne dystrophy: Study of long‐term effectMuscle & Nerve, 1994
- Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular DystrophyNew England Journal of Medicine, 1989
- PREDNISONE IN DUCHENNE MUSCULAR DYSTROPHYThe Lancet, 1974